%0 Journal Article
%A Hoberger, Michael
%A Zuber, Romy L
%A Burkhard-Meier, Anton
%A Di Gioia, Dorit
%A Jurinovic, Vindi
%A Völkl, Michael
%A Güler, Sinan E
%A Albertsmeier, Markus
%A Klein, Alexander
%A Dürr, Hans Roland
%A Schmidt-Hegemann, Nina-Sophie
%A Knösel, Thomas
%A Kunz, Wolfgang G
%A von Bergwelt-Baildon, Michael
%A Lindner, Lars H
%A Berclaz, Luc M
%T Long-term benefit from high-dose ifosfamide in sarcoma depends on sustained prior control and timely intervention: a machine learning analysis.
%J Journal of cancer research and clinical oncology
%V 152
%N 1
%@ 0301-1585
%C Heidelberg
%I Springer
%M DKFZ-2026-00074
%P 34
%D 2026
%Z #DKTKZFB9#
%X High-dose ifosfamide (HD-IFO) remains an effective regimen for advanced bone and soft tissue sarcomas, but predictors of long-term benefit are poorly defined. This study evaluated clinical outcomes and prognostic factors using machine learning-assisted modeling in sarcoma patients treated with HD-IFO at a high-volume academic center.We retrospectively analyzed 26 patients with histologically confirmed bone or soft tissue sarcoma who received HD-IFO (≥ 12 g/m2 per cycle) between 2015 and 2025. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method and compared across RECIST response categories using log-rank testing. Prognostic factors were identified using Least Absolute Shrinkage and Selection Operator (LASSO) logistic regression with leave-one-out cross-validation. The top three variables were entered into multivariable logistic regression to estimate odds ratios (ORs) for OS > 24 months.Median PFS and OS from start of HD-IFO was 6.6 months (95
%K Humans
%K Ifosfamide: administration & dosage
%K Ifosfamide: therapeutic use
%K Female
%K Male
%K Machine Learning
%K Middle Aged
%K Retrospective Studies
%K Sarcoma: drug therapy
%K Sarcoma: pathology
%K Sarcoma: mortality
%K Adult
%K Antineoplastic Agents, Alkylating: administration & dosage
%K Antineoplastic Agents, Alkylating: therapeutic use
%K Aged
%K Young Adult
%K Prognosis
%K Bone Neoplasms: drug therapy
%K Bone Neoplasms: pathology
%K Bone Neoplasms: mortality
%K Adolescent
%K Bone sarcoma (Other)
%K High-dose ifosfamide (Other)
%K Machine learning-assisted modeling (Other)
%K Soft tissue sarcoma (Other)
%K Ifosfamide (NLM Chemicals)
%K Antineoplastic Agents, Alkylating (NLM Chemicals)
%F PUB:(DE-HGF)16
%9 Journal Article
%$ pmid:41504936
%R 10.1007/s00432-025-06410-8
%U https://inrepo02.dkfz.de/record/307579